 | |
| Clinical data | |
|---|---|
| Trade names | Maxicam |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.047.334 |
| Chemical and physical data | |
| Formula | C14H13N3O5S |
| Molar mass | 335.33 g·mol−1 |
| 3D model (JSmol) | |
| |
Isoxicam is a nonsteroidal anti-inflammatory drug (NSAID) that was taken or applied to reduce inflammation and as an analgesic reducing pain in certain conditions. The drug was introduced in 1983 by the Warner-Lambert Company. Isoxicam is a chemical analog of piroxicam (Feldene) which has a pyridine ring in lieu of an isoxazole ring. In 1985 Isoxicam was withdrawn from the French market, due to adverse effects, namely Toxic Epidermal Necrolysis (Lyell syndrome) resulting in death. Although these serious side effects were observed only in France, the drug was withdrawn worldwide.
|
pyrazolones / pyrazolidines |
|
|---|---|
| salicylates | |
|
acetic acid derivatives and related substances |
|
| oxicams | |
|
propionic acid derivatives (profens) |
|
|
n-arylanthranilic acids (fenamates) |
|
|
COX-2 inhibitors (coxibs) |
|
| other | |
| NSAID combinations |
|
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
